NASDAQ · NTRA
Natera, Inc.
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
Loading market information…
NASDAQ · GH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Guardant Health, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Guardant Health, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 30, 2025 | -$0.77+1.28% vs estimate | $203.47M+7.03% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | -$0.90-20.0% vs estimate | $201.81M+5.04% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.88-60.0% vs estimate | $191.48M+12.31% vs estimate |
|---|
THE ANALYST VIEW
31 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 15 contributors · Median target $200.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$436.00+$11.58 (+2.73%)
Natera, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.32% below the high.
$158.92+$1.04 (+0.66%)
GRAIL Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.54% below the high.
$114.84+$0.84 (+0.74%)
BillionToOne, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.66% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$15.93-$0.08 (-0.47%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$38.51+$1.83 (+4.99%)
Castle Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.03% below the high.
$6.67+$0.04 (+0.6%)
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
$21.68+$0.16 (+0.74%)
Fulgent Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.15% below the high.
